LogiPharma Europe 2025: Inside Sanofi’s Shift Toward a Data-Driven Supply Chain Model

PC: You recently delivered a keynote presentation surrounding “How to Integrate E2E and Deliver ‘Miracles of Science’ to your Patients.” Could you provide a brief synopsis of what your session entailed?

Beadle: Sanofi is undergoing a major transformation with the ambition to become the first biopharma company powered by AI at scale. To achieve that, we need a smart, end-to-end supply chain—one that spans from the patient all the way back to the supplier. It must be data-driven and digitally led, allowing us to predict and prevent potential disruptions.

We took key lessons from the COVID-19 pandemic, and over the past three years, we've been actively transforming our supply chain. While the journey isn’t over, we’ve completed chapter one and are now beginning chapter two. So far, we've made tremendous progress across demand, supply, and logistics. We've revamped our operating model, upskilled our teams, and harnessed digital and AI tools to drive performance.

As a result, we’ve seen a 12% improvement in service and a 14-point gain in cost-to-serve efficiency. This shows that by fully integrating digital and AI into everyday operations, you really can have it all.

Full Interview Summary: Sanofi is in the midst of a significant digital transformation, with the goal of becoming the first biopharma company powered by AI at scale. A major component of that vision is building a “smart supply chain”—an end-to-end, data-driven, and digitally enabled system that provides visibility from suppliers all the way to patients. This transformation has already led to measurable results, including a 12% improvement in service levels and a 14-point gain in cost-to-serve efficiency. By eliminating outdated Excel-based workflows and implementing advanced planning and ERP systems, Sanofi has increased visibility and responsiveness across its operations.

Sustainability is another major focus. Sanofi aims to be carbon neutral by 2030 and achieve net-zero greenhouse gas emissions by 2045. Compared to 2019 levels, the company has already reduced Scope 1 and 2 emissions by 47% and Scope 3 emissions by 10%. To reach these goals, Sanofi is shifting away from air freight—used only when life-saving products require it—and investing more in sea and rail transport. The company has even piloted shipments using sailing vessels to further reduce its environmental footprint.

Reflecting on the event, Beadle highlighted the value of engaging with peers across the industry. Sessions on reimagining operations and sustainability reinforced Sanofi’s direction, while also prompting her to consider how the company can continue accelerating progress and adapting in a rapidly evolving healthcare landscape.